Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

, /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. Quarter Ended Dollars in millions, except per share data March 31, December 31, March 31, Change 2025 2024 2024 Prior Qtr Prior Yr. Revenue from Continuing Operations $ 143 $ 148 $ 136 (3) % 5 % Organic growth 6 % Sample Management Solutions $ 80 $ 81 $ 74 (2) % 8 % Multiomics $ 64 $ 66 $ 62 (4) % 2 % Diluted EPS Continuing Operations $ (0.40) $ (0.21) $ (0.29) (93) % (36) % Diluted EPS Total $ (0.88) $ (0.29) $ (2.47) NM 64 % Non-GAAP Diluted EPS Continuing Operations $ 0.05 $ 0.08 $ 0.06 (43) % (23) % Adjusted EBITDA - Continuing Operations $ 14 $ 13 $ 8 7 % 75 % Adjusted EBITDA Margin - Continuing Operations 10.0 % 9.0 % 6.0 % Management Comments "We delivered another quarter of strong performance in an evolving and uncertain macroeconomic environment. Our performance in the second quarter and first half of our fiscal year demonstrates the resilience of our portfolio and the dedication of our teams that focus on our customers with our clearly differentiated products and services," said John Marotta, President and CEO. "We have a healthy balance sheet, and strong cash position, which provides optionality to continue investing in our long-term growth plans while maintaining our continued disciplined in capital deployment. We remain confident in our positioning and disciplined in how we operate the business while navigating these uncertain times." Second Quarter Fiscal 2025 Results - Continuing Operations Revenue was $143 million, up 5% year over year. Organic revenue, which excludes the impact from foreign exchange, was up 6% year over year. The year-over-year revenue increase was attributable to higher Sample Management Solutions and Multiomics revenues. Sample Management Solutions revenue was $80 million, up 8% year over year. Organic revenue grew 8%, mainly driven by higher revenues in Sample Repository Solutions and Core Products, particularly in Consumables and Instruments, Sample Storage, Clinical Stores and Product Services. Multiomics revenue was $64 million, up 2% year over year. Organic revenue grew 3% year over year, primarily driven by growth in Next Generation Sequencing, partially offset by a year-over-year decline in Sanger Sequencing and Gene Synthesis. Summary of GAAP Earnings Results - Continuing Operations Operating loss was $16 million. Operating margin was (11.3%), up 650 basis points year over year. Gross margin was 45.9%, up 140 basis points year over year, mainly driven by higher revenue, favorable sales mix and operational efficiencies. Operating expenses were $82 million, down 3% year over year, primarily due to lower research and development expense and the impact of non-recurring intangible asset impairment charges recorded in the same period last year. These were partially offset by higher selling, general and administrative expenses, as well as increased restructuring and transformation charges. Other income included $4 million of net interest income versus $9.5 million in the prior year period. Diluted EPS from continuing operations was ($0.40) compared to ($0.29) in the second quarter of fiscal year 2024. Diluted EPS from discontinued operations was ($0.49). Total diluted EPS was ($0.88), compared to ($2.47) a year ago. Summary of Non-GAAP Earnings Results - Continuing Operations Adjusted operating loss was $0.6 million. Adjusted operating margin was (0.4%), an improvement of 280 basis points year over year. Adjusted gross margin was 47.5%, up 130 basis points compared to the second quarter of fiscal 2024, primarily driven by higher revenue, favorable sales mix and operating efficiencies. Adjusted operating expense in the quarter was $69 million, up 2% year over year, primarily driven by higher selling, general and administrative expenses, partially offset by lower research and development costs. Adjusted EBITDA was $14 million, and Adjusted EBITDA margin was 10.0%, an improvement of 400 basis points year over year. Non-GAAP Diluted EPS was $0.05, compared to $0.06 one year ago. Cash and Liquidity as of March 31, 2025 The Company ended the quarter with a total balance of cash, cash equivalents, restricted cash and marketable securities of $540 million, which includes $27 million of cash held in discontinued operations. Operating cash flow was $14 million in the quarter. Capital expenditures were $7 million, and free cash flow (cash flow from operations less capital expenditures) was $7 million. Guidance for Continuing Operations for Full Year Fiscal 2025 The Company is reiterating its revenue guidance for fiscal year 2025: Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024. Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2024. Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures costs, governance-related matters, goodwill and intangible impairments, and other gains and charges that are not representative of the normal operations of the business. Conference Call and Webcast Azenta management will webcast its second quarter fiscal 2025 earnings conference call today at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed. The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events and will be archived online on this website for convenient on-demand replay. Regulation G – Use of Non-GAAP financial Measures The Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a better perspective on the results of business operations, which the Company believes is more comparable to the similar analyses provided by its peers. These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets and statements of operations. Certain amounts in the tables that supplement the consolidated financial statements may not sum due to rounding. All percentages are calculated using unrounded amounts. "Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934 Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Forward-looking statements include but are not limited to statements about our revenue and earnings expectations, our ability to realize margin improvement from cost reductions, and our ability to deliver financial success in the future and otherwise related to future operating or financial performance and opportunities. Factors that could cause results to differ from our expectations include the following: uncertainties in global political and economic conditions, including the imposition of additional tariffs on goods imported into the US, our ability to reduce costs effectively; the volatility of the life sciences markets the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; price competition; disputes concerning intellectual property; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstance on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release. About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com. AZENTA INVESTOR CONTACTS: Yvonne PerronVice President, Financial Planning & Analysis and Investor Relations[email protected] Sherry Dinsmore[email protected] AZENTA, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (In thousands, except per share data) Three Months Ended Six Months Ended March 31, March 31, 2025 2024 2025 2024 Revenue Products $ 41,955 $ 38,772 $ 85,782 $ 82,479 Services 101,463 97,583 205,146 195,601 Total revenue 143,418 136,355 290,928 278,080 Cost of revenue Products 23,159 24,015 48,493 50,798 Services 54,373 51,676 107,878 104,875 Total cost of revenue 77,532 75,691 156,371 155,673 Gross profit 65,886 60,664 134,557 122,407 Operating expenses Research and development 6,869 7,733 13,249 15,046 Selling, general and administrative 71,588 69,058 144,801 138,947 Impairment of intangible assets — 4,658 — 4,658 Restructuring charges 3,580 3,428 4,011 4,214 Total operating expenses 82,037 84,877 162,061 162,865 Operating loss (16,151) (24,213) (27,504) (40,458) Other income Interest income, net 4,489 9,479 8,787 19,434 Other income (expense), net 1,157 (268) 2,360 250 Loss before income taxes (10,505) (15,002) (16,357) (20,774) Income tax expense 7,680 1,200 11,249 2,620 Loss from continuing operations (18,185) (16,202) (27,606) (23,394) Loss from discontinued operations, net of tax (22,271) (120,678) (26,190) (129,210) Net loss $ (40,456) $ (136,880) $ (53,796) $ (152,604) Basic net loss per share: Loss from continuing operations $ (0.40) $ (0.29) $ (0.60) $ (0.42) Loss from discontinued operations, net of tax (0.49) (2.18) (0.57) (2.30) Basic net loss per share $ (0.88) $ (2.47) $ (1.18) $ (2.72) Diluted net loss per share: Loss from continuing operations $ (0.40) $ (0.29) $ (0.60) $ (0.42) Loss from discontinued operations, net of tax (0.49) (2.18) (0.57) (2.30) Diluted net loss per share $ (0.88) $ (2.47) $ (1.18) $ (2.72) Weighted average shares used in computing net loss per share: Basic 45,732 55,440 45,658 56,078 Diluted 45,732 55,440 45,658 56,078 AZENTA, INC. CONSOLIDATED BALANCE SHEETS (unaudited) (In thousands, except share and per share data) March 31, September 30, 2025 2024 Assets Current assets Cash and cash equivalents $ 253,642 $ 280,030 Short-term marketable securities 74,697 151,162 Accounts receivable, net of allowance for expected credit losses ($5,624 and $5,349, respectively) 149,490 156,273 Inventories 83,321 78,923 Short-term restricted cash 2,102 2,069 Prepaid expenses and other current assets 67,590 75,456 Current assets held for sale 79,754 88,894 Total current assets 710,596 832,807 Property, plant and equipment, net 151,716 155,622 Long-term marketable securities 176,781 49,454 Long-term deferred tax assets 731 837 Operating lease right-of-use assets 59,856 60,406 Goodwill 682,955 691,409 Intangible assets, net 111,202 125,042 Other assets 7,125 10,670 Noncurrent assets held for sale 140,963 173,794 Total assets $ 2,041,925 $ 2,100,041 Liabilities and stockholders' equity Current liabilities Accounts payable $ 39,155 $ 33,344 Deferred revenue 41,608 30,493 Accrued warranty and retrofit costs 5,237 5,213 Accrued compensation and benefits 26,039 27,785 Accrued customer deposits 26,318 22,324 Accrued income taxes payable 10,321 9,266 Accrued expenses and other current liabilities 43,102 46,364 Current liabilities held for sale 28,933 30,050 Total current liabilities 220,713 204,839 Long-term tax reserves 417 398 Long-term deferred tax liabilities 22,458 18,084 Long-term operating lease liabilities 53,696 56,683 Other long-term liabilities 10,062 8,874 Noncurrent liabilities held for sale 33,087 42,196 Total liabilities 340,433 331,074 Stockholders' equity Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding — — Common stock, $0.01 par value - 125,000,000 shares authorized, 59,237,887 shares issued and 45,776,018 shares outstanding at March 31, 2025; 59,031,953 shares issued and 45,570,084 shares outstanding at September 30, 2024 593 590 Additional paid-in capital 520,961 505,958 Accumulated other comprehensive loss (42,149) (13,464) Treasury stock, at cost - 13,461,869 shares at March 31, 2025 and September 30, 2024 (200,956) (200,956) Retained earnings 1,423,043 1,476,839 Total stockholders' equity 1,701,492 1,768,967 Total liabilities and stockholders' equity $ 2,041,925 $ 2,100,041 AZENTA, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (In thousands) Six Months Ended March 31, 2025 2024 Cash flows from operating activities Net loss $ (53,796) $ (152,604) Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and amortization 32,053 44,214 Impairment of goodwill and intangible assets — 115,975 Loss on assets held for sale 24,187 — Inventory write-downs and other asset write-offs 4,326 7,499 Stock-based compensation 13,453 8,804 Amortization and accretion on marketable securities (983) (2,084) Deferred income taxes (1,885) (9,456) (Gain) loss on disposals of property, plant and equipment (7) 260 Changes in operating assets and liabilities: Accounts receivable 6,713 2,922 Inventories (6,030) 8,238 Accounts payable 1,864 936 Deferred revenue 12,042 3,379 Accrued warranty and retrofit costs 343 (714) Accrued compensation and tax withholdings (2,379) (7,831) Accrued restructuring costs 1,548 1,454 Other assets and liabilities 12,752 1,379 Net cash provided by operating activities 44,201 22,371 Cash flows from investing activities Purchases of property, plant and equipment (15,158) (19,542) Purchases of marketable securities (236,237) (345,447) Sales and maturities of marketable securities 184,636 190,504 Proceeds from other investment 2,130 — Net investment hedge settlement 3,043 1,476 Net cash used in investing activities (61,586) (173,009) Cash flows from financing activities Proceeds from issuance of common stock 1,553 1,678 Payments of finance leases (457) (386) Share repurchases — (186,834) Excise tax payment for settled share repurchases (11,376) — Net cash used in financing activities (10,280) (185,542) Effects of exchange rate changes on cash, cash equivalents and restricted cash (4,459) 16,255 Net decrease in cash, cash equivalents and restricted cash (32,124) (319,925) Cash, cash equivalents and restricted cash, beginning of period 320,990 684,045 Cash, cash equivalents and restricted cash, end of period $ 288,866 $ 364,120 Supplemental disclosures: Cash (received) / paid for income taxes, net (4,594) 5,008 Purchases of property, plant and equipment included in accounts payable and accrued expenses 5,773 2,270 Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets March 31, September 30, 2025 2024 Cash and cash equivalents of continuing operations $ 253,642 $ 280,030 Cash included in current assets held for sale 27,025 30,899 Short-term restricted cash 2,102 2,069 Long-term restricted cash included in other assets 6,097 7,992 Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows $ 288,866 $ 320,990 Notes on Non-GAAP Financial Measures - Continuing Operations Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, non-recurring costs related to the Company's business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure. Quarter Ended March 31, 2025 December 31, 2024 March 31, 2024 per diluted per diluted per diluted Amounts in thousands, except per share data $ share $ share $ share Net loss from continuing operations $ (18,185) $ (0.40) $ (9,421) $ (0.21) $ (16,202) $ (0.29) Adjustments: Amortization of completed technology 2,308 0.05 1,500 0.03 2,067 0.04 Amortization of other intangible assets 3,803 0.08 4,573 0.10 5,152 0.09 Transformation costs(1) 5,183 0.11 3,046 0.07 4,095 0.07 Restructuring charges 3,580 0.08 431 0.01 3,428 0.06 Impairment of intangible assets — — — — 4,658 0.08 Merger and acquisition costs and costs related to share repurchase(2) 688 0.02 1,570 0.03 426 0.01 Investment income(3) (2,130) (0.05) — — — — Tax adjustments(4) 6,900 0.15 408 0.01 1,645 0.03 Tax effect of adjustments (40) (0.00) 1,530 0.03 (1,959) (0.04) Non-GAAP adjusted net income from continuing operations $ 2,107 $ 0.05 $ 3,637 $ 0.08 $ 3,310 $ 0.06 Stock-based compensation, pre-tax 8,031 0.18 4,872 0.11 5,410 0.10 Tax rate 17 % — 15 % — 12 % — Stock-based compensation, net of tax 6,690 0.15 4,141 0.09 4,761 0.09 Non-GAAP adjusted net income excluding stock-based compensation - continuing operations $ 8,797 $ 0.19 $ 7,778 $ 0.17 $ 8,071 $ 0.15 Shares used in computing non-GAAP diluted net income per share — 45,732 — 45,626 — 55,440 Six Months Ended March 31, 2025 March 31, 2024 per diluted per diluted Amounts in thousands, except per share data $ share $ share Net loss from continuing operations $ (27,606) $ (0.60) $ (23,394) $ (0.42) Adjustments: Amortization of completed technology 3,808 0.08 3,923 0.07 Amortization of other intangible assets 8,376 0.18 10,523 0.19 Transformation costs(1) 8,229 0.18 4,136 0.07 Restructuring charges 4,011 0.09 4,214 0.08 Impairment of intangible assets — — 4,658 0.08 Merger and acquisition costs and costs related to share repurchase(2) 2,258 0.05 4,747 0.08 Investment income(3) (2,130) (0.05) — — Tax adjustments(4) 7,308 0.16 3,338 0.06 Tax effect of adjustments 1,490 0.03 (4,288) (0.08) Non-GAAP adjusted net income from continuing operations $ 5,744 $ 0.13 $ 7,857 $ 0.14 Stock-based compensation, pre-tax 12,904 0.28 8,411 0.15 Tax rate 17 % — 12 % — Stock-based compensation, net of tax 10,749 0.24 7,402 0.13 Non-GAAP adjusted net income excluding stock-based compensation - continuing operations $ 16,493 $ 0.36 $ 15,259 $ 0.27 Shares used in computing non-GAAP diluted net income per share — 45,658 — 56,078 (1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. (2) Includes expenses related to governance-related matters. (3) The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis during the three months ended March 31, 2025. The gain is non-recurring and non-operational in nature. (4) Tax adjustments during all periods include adjustments to tax benefits related to stock compensation. These adjustments are recognized in the period of vesting for US GAAP but included in the annual effective tax rate for Non-GAAP reporting. Tax adjustments for the three and six months ended March 31, 2025 include $6.6 million of tax expenses related to a one-time repatriation of historical earnings from China. Quarter Ended Six Months Ended March 31, December 31, March 31, March 31, March 31, Dollars in thousands 2025 2024 2024 2025 2024 GAAP net loss $ (40,456) $ (13,340) $ (136,880) $ (53,796) $ (152,604) Less: Loss from discontinued operations (22,271) (3,919) (120,678) (26,190) (129,210) GAAP net loss from continuing operations (18,185) (9,421) (16,202) (27,606) (23,394) Adjustments: Interest income, net (4,489) (4,298) (9,479) (8,787) (19,434) Income tax expense 7,680 3,569 1,200 11,249 2,620 Depreciation 7,818 7,474 7,395 15,292 14,815 Amortization of completed technology 2,308 1,500 2,067 3,808 3,923 Amortization of other intangible assets 3,803 4,573 5,152 8,376 10,523 Earnings before interest, taxes, depreciation and amortization - Continuing operations $ (1,065) $ 3,397 $ (9,867) $ 2,332 $ (10,947) Quarter Ended Six Months Ended March 31, December 31, March 31, March 31, March 31, Dollars in thousands 2025 2024 2024 2025 2024 Earnings before interest, taxes, depreciation and amortization - Continuing operations $ (1,065) $ 3,397 $ (9,867) $ 2,332 $ (10,947) Adjustments: Stock-based compensation 8,031 4,872 5,410 12,904 8,411 Restructuring charges 3,580 431 3,428 4,011 4,214 Impairment of intangible assets — — 4,658 — 4,658 Merger and acquisition costs and costs related to share repurchase(1) 688 1,570 426 2,258 4,747 Transformation costs(2) 5,183 3,046 4,095 8,229 4,136 Investment income(3) (2,130) — — (2,130) — Adjusted earnings before interest, taxes, depreciation and amortization - Continuing operations $ 14,287 $ 13,316 $ 8,150 $ 27,604 $ 15,219 (1) Includes expenses related to governance-related matters. (2) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. (3) The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis during the three months ended March 31, 2025. The gain is non-recurring and non-operational in nature. Quarter Ended Dollars in thousands March 31, 2025 December 31, 2024 March 31, 2024 GAAP gross profit $ 65,886 45.9 % $ 68,671 46.6 % $ 60,664 44.5 % Adjustments: Amortization of completed technology 2,308 1.6 % 1,500 1.0 % 2,067 1.5 % Transformation costs(1) — — % 52 0.0 % 359 0.3 % Other adjustments (9) (0.0) % 6 0.0 % — — % Non-GAAP adjusted gross profit $ 68,185 47.5 % $ 70,229 47.6 % $ 63,091 46.3 % Six Months Ended Dollars in thousands March 31, 2025 March 31, 2024 GAAP gross profit $ 134,557 46.3 % $ 122,407 44.0 % Adjustments: Amortization of completed technology 3,808 1.3 % 3,923 1.4 % Transformation costs(1) 52 0.0 % 359 0.1 % Non-GAAP adjusted gross profit $ 138,417 47.6 % $ 126,689 45.6 % (1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. Sample Management Solutions Multiomics Quarter Ended Quarter Ended March 31, December 31, March 31, March 31, December 31, March 31, Dollars in thousands 2025 2024 2024 2025 2024 2024 GAAP gross profit $ 38,251 47.9 % $ 38,114 46.9 % $ 32,943 44.4 % $ 27,635 43.5 % $ 30,557 46.1 % $ 27,721 44.6 % Adjustments: Amortization of completed technology 1,449 1.8 % 639 0.8 % 1,028 1.4 % 859 1.4 % 861 1.3 % 1,040 1.7 % Transformation costs(1) — — % 52 0.1 % 359 0.5 % — — % — — % — — % Other adjustment (9) (0.0) % 5 0.0 % — — % — — % 1 — % — — % Non-GAAP adjusted gross profit $ 39,691 49.7 % $ 38,810 47.8 % $ 34,330 46.3 % $ 28,494 44.9 % $ 31,419 47.4 % $ 28,761 46.2 % Segment Total Quarter Ended March 31, December 31, March 31, Dollars in thousands 2025 2024 2024 GAAP gross profit $ 65,886 45.9 % $ 68,671 46.6 % $ 60,664 44.5 % Adjustments: Amortization of completed technology 2,308 1.6 % 1,500 1.0 % 2,068 1.5 % Transformation costs(1) — — % 52 0.0 % 359 0.3 % Other adjustment (9) (0.0) % 6 0.0 % — — % Non-GAAP adjusted gross profit $ 68,185 47.5 % $ 70,229 47.6 % $ 63,091 46.3 % Sample Management Solutions Multiomics Six Months Ended Six Months Ended Dollars in thousands March 31, 2025 March 31, 2024 March 31, 2025 March 31, 2024 GAAP gross profit $ 76,366 47.4 % $ 66,215 43.2 % $ 58,191 44.8 % $ 56,192 45.0 % Adjustments: Amortization of completed technology 2,088 1.3 % 1,843 1.4 % 1,720 1.3 % 2,080 1.7 % Transformation costs(1) 52 0.0 % 359 0.3 % — — % — — % Non-GAAP adjusted gross profit $ 78,506 48.7 % $ 68,417 44.7 % $ 59,911 46.2 % $ 58,272 46.6 % Segment Total Six Months Ended Dollars in thousands March 31, 2025 March 31, 2024 GAAP gross profit $ 134,557 46.3 % $ 122,407 44.0 % Adjustments: Amortization of completed technology 3,808 1.3 % 3,923 1.4 % Transformation costs(1) 52 0.0 % 359 0.1 % Non-GAAP adjusted gross profit $ 138,417 47.6 % $ 126,689 45.6 % (1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. Sample Management Solutions Multiomics Quarter Ended Quarter Ended March 31, December 31, March 31, March 31, December 31, March 31, Dollars in thousands 2025 2024 2024 2025 2024 2024 GAAP operating income (loss) $ 567 $ 1,562 $ (2,894) $ (6,132) $ (3,387) $ (3,920) Adjustments: Amortization of completed technology 1,449 639 1,028 859 861 1,040 Amortization of other intangible assets — 13 52 — — — Transformation costs(1) 2,606 103 359 — — — Restructuring charges — — — (23) 23 — Other adjustments (9) — (2) — — — Non-GAAP adjusted operating income (loss) $ 4,613 $ 2,317 $ (1,457) $ (5,296) $ (2,503) $ (2,880) Total Segments Corporate Total Quarter Ended Quarter Ended Quarter Ended March 31, December 31, March 31, March 31, December 31, March 31, March 31, December 31, March 31, Dollars in thousands 2025 2024 2024 2025 2024 2024 2025 2024 2024 GAAP operating income (loss) $ (5,565) $ (1,825) $ (6,814) $ (10,586) $ (9,528) $ (17,399) $ (16,151) $ (11,353) $ (24,213) Adjustments: Amortization of completed technology 2,308 1,500 2,068 — — (1) 2,308 1,500 2,067 Amortization of other intangible assets — 13 52 3,803 4,560 5,100 3,803 4,573 5,152 Transformation costs(1) 2,606 103 359 2,577 2,943 3,736 5,183 3,046 4,095 Restructuring charges (23) 23 — 3,603 408 3,428 3,580 431 3,428 Impairment of intangible assets — — — — — 4,658 — — 4,658 Merger and acquisition costs and costs related to share repurchase(2) — — — 688 1,570 426 688 1,570 426 Other adjustments (9) — (2) — 9 2 (9) 9 — Non-GAAP adjusted operating income (loss) $ (683) $ (186) $ (4,337) $ 85 $ (38) $ (50) $ (598) $ (224) $ (4,387) Sample Management Solutions Multiomics Six Months Ended Six Months Ended Dollars in thousands March 31, March 31, March 31, March 31, 2025 2024 2025 2024 GAAP operating income (loss) $ 2,129 $ (4,380) $ (9,519) $ (8,223) Adjustments: Amortization of completed technology 2,088 1,843 1,720 2,080 Amortization of other intangible assets — 103 — — Transformation costs(1) 2,709 359 — — Other adjustments 4 2 3 (1) Non-GAAP adjusted operating income (loss) $ 6,930 $ (2,073) $ (7,796) $ (6,144) Total Segments Corporate Total Six Months Ended Six Months Ended Six Months Ended Dollars in thousands March 31, March 31, March 31, March 31, March 31, March 31, 2024 2024 2025 2024 2025 2024 GAAP operating loss $ (7,390) $ (12,603) $ (20,114) $ (27,855) $ (27,504) $ (40,458) Adjustments: Amortization of completed technology 3,808 3,923 — — 3,808 3,923 Amortization of other intangible assets — 103 8,376 10,420 8,376 10,523 Transformation costs(1) 2,709 359 5,520 3,777 8,229 4,136 Restructuring charges — — 4,011 4,214 4,011 4,214 Impairment of intangible assets — — — 4,658 — 4,658 Merger and acquisition costs and costs related to share repurchase(2) — — 2,258 4,747 2,258 4,747 Other adjustments 7 1 (7) (2) — (1) Non-GAAP adjusted operating income (loss) $ (866) $ (8,217) $ 44 $ (41) $ (822) $ (8,258) (1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company's 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design. (2) Includes expenses related to governance-related matters. Sample Management Solutions Multiomics Azenta Total Quarter Ended Quarter Ended Quarter Ended March 31, March 31, March 31, March 31, March 31, March 31, Dollars in millions 2025 2024 Change 2025 2024 Change 2025 2024 Change Revenue $ 80 $ 74 8 % $ 64 $ 62 2 % $ 143 $ 136 5 % Currency exchange rates 0 — 1 % 1 — 1 % 1 — 1 % Organic revenue $ 80 $ 74 8 % $ 64 $ 62 3 % $ 144 $ 136 6 % Sample Management Solutions Multiomics Azenta Total Six Months Ended Six Months Ended Six Months Ended March 31, March 31, March 31, March 31, March 31, March 31, Dollars in millions 2025 2024 Change 2025 2024 Change 2025 2024 Change Revenue $ 161 $ 153 5 % $ 130 $ 125 4 % $291 $ 278 5 % Currency exchange rates 0 — 0 % 1 — 0 % 1 — 0 % Organic revenue $ 161 $ 153 5 % $ 130 $ 125 4 % $ 292 $278 5 % SOURCE Azenta WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025

FAQ

Why Neutral?

How important is it?

Why Short Term?

Related Companies

Related News